

AMENDMENTS TO THE CLAIMS

Please insert the following listing of the claims into the Substitute Specification, immediately prior to the Abstract.

1. (Currently Amended) A pharmaceutical composition comprising a compound comprising the tetrapeptide motif D/E-D/E-G/K-W (SEQ ID NO: 2), and a pharmaceutically acceptable carrier.

2. (Currently Amended) The pharmaceutical composition according to claim 1, wherein the tetrapeptide motif is DDGW (SEQ ID NO: 2).

3. (Currently Amended) Use of a compound comprising the tetrapeptide motif D/E-D/E-G/K-W (SEQ ID NO: 2) for the manufacture of a pharmaceutical composition for the treatment of conditions dependent on leukocyte migration.

4. (Original) Use according to claim 3 wherein the condition dependent on leukocyte migration is leukaemia.

5. (Original) Use according to claim 3 for the manufacture of a pharmaceutical composition for inhibiting the adhesion of progelatinases to β_2 -integrins.

6. (Currently Amended) Use of the compound comprising the tetrapeptide motif D/E-D/E-G/K-W (SEQ ID NO: 2) for the manufacture of a pharmaceutical composition for prophylaxis and treatment of conditions dependent on neutrophil migration.

7. (Original) Use according to claim 6 for the manufacture of a pharmaceutical composition for prophylaxis and treatment of inflammatory conditions.

8. (Currently Amended) Use according to claim 3, wherein the tetrapeptide motif is DDGW (SEQ ID NO: 2).

9. (Currently Amended) A method for therapeutic or prophylactic treatment of conditions dependent on leukocyte migration, comprising administering to a mammal in need of such treatment a compound comprising the tetrapeptide motif D/E-D/E-G/K-W (SEQ ID NO: 2) in an amount which is effective in inhibiting leukocyte migration.

10. (Currently Amended) A method for therapeutic or prophylactic treatment of conditions dependent on neutrophil migration, comprising administering to a mammal in need of such treatment a compound comprising the tetrapeptide motif D/E-D/E-G/K-W (SEQ ID NO: 2) in an amount which is effective in inhibiting neutrophil migration.

11. (Currently Amended) A method for therapeutic or prophylactic treatment of leukaemia, comprising administering to a mammal in need of such treatment a compound comprising the tetrapeptide motif D/E-D/E-G/K-W (SEQ ID NO: 2) in an amount which is effective in inhibiting leukaemia cell migration.

12. (Currently Amended) A method for therapeutic or prophylactic treatment of inflammatory conditions, comprising administering to a mammal in need of such treatment a compound comprising the tetrapeptide motif D/E-D/E-G/K-W (SEQ ID NO: 2) in an amount which is effective in inhibiting neutrophil migration.

13. (Currently Amended) The method according to claim 9, wherein the tetrapeptide motif is DDGW (SEQ ID NO: 2).